Schering-Plough Corporation announced an agreement under which Reckitt Benckiser plc will buy back Schering-Plough's U.S. marketing rights for Suboxone (buprenorphine hydrochloride/naloxone hydrochloride) and Subutex (buprenorphine hydrochloride) sublingual tablets for the treatment of opioid dependence.

Schering-Plough said it agreed to sell back U.S. rights to these products in order to remain focused on its core U.S. therapeutic areas.

Schering-Plough will maintain exclusive international distribution rights (excluding Japan, Taiwan, Korea, Australia and New Zealand) to these products. Financial details are not being disclosed.